Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment - Archive ouverte HAL Access content directly
Journal Articles BMC Infectious Diseases Year : 2014

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment

(1) , (1) , (2) , (3) , (4) , (5) , (6) , (7, 8) , (9) , (1, 10)
1
2
3
4
5
6
7
8
9
10
Fichier principal
Vignette du fichier
1471-2334-14-S2-P83.pdf (63.7 Ko) Télécharger le fichier
Vignette du fichier
1471-2334-14-S2-P83.xml (6.33 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Dates and versions

inserm-00995738 , version 1 (23-05-2014)

Identifiers

  • HAL Id : inserm-00995738 , version 1

Cite

Anne-Sophie Chantry, M Tching-Sin, Catherine Dhiver, Thierry Allegre, Jean-Marie Ruiz, et al.. Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment. BMC Infectious Diseases, 2014, 14 (Suppl 2), pp.P83. ⟨inserm-00995738⟩

Collections

INSERM UNIV-AMU
151 View
631 Download

Share

Gmail Facebook Twitter LinkedIn More